Saltar al contenido

Haemonetics Corp (HAE) stock: revenue, earnings & dividend

Haemonetics Corp (HAE, NYSE): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener HAE · NYSE Medizintechnik & Messgeräte US-MA

Key figures

Fiscal year
2025
Revenue
1.33 bn $
Revenue growth
-2 %
Revenue growth 5y (p.a.)
–
Net income
97,308 $
Net margin
0 %
Operating margin
11.8 %
Earnings per share (diluted)
2.05 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
2.49 bn $
Equity
911 m $
Equity ratio
36.6 %
Return on equity
0 %
Cash
363 m $
Operating cash flow
293 m $
Free cash flow
260 m $
Shares outstanding
45,537,511

History

Revenue by fiscal year

2021 993 m $
2022 1.17 bn $
2023 1.31 bn $
2024 1.36 bn $
2025 1.33 bn $

Net income by fiscal year

2016 -26.27 m $
2017 45.6 m $
2018 55 m $
2019 76.5 m $
2020 79.5 m $
2021 43.4 m $
2022 115 m $
2023 118 m $
2024 167,679 $
2025 97,308 $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20251.33 bn $97,308 $2.05 $–293 m $
20241.36 bn $167,679 $3.31 $–182 m $
20231.31 bn $118 m $2.29 $–182 m $
20221.17 bn $115 m $2.24 $–273 m $
2021993 m $43.4 m $0.84 $–172 m $
2020–79.5 m $1.55 $–109 m $
2019–76.5 m $1.48 $–158 m $
2018–55 m $1.04 $–159 m $
2017–45.6 m $0.85 $–220 m $
2016–-26.27 m $-0.51 $–160 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)